Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Simcere Acquires China Rights to Novel Stroke Drug from Canadian Biotech

publication date: May 12, 2020

Nanjing's Simcere Pharma has acquired greater China rights to a novel product aimed at treating stroke from Canada's Primary Peptides. In 2014, Primary Peptides was spun out of the University of British Columbia to develop drugs based on preventing protein toxic cascades that kill brain cells due to trauma, stroke or disease. It out-licensed its first product to Yabao Pharma of Beijing in a $40 million agreement. Simcere will have rights to the candidate in mainland China, Hong Kong, Macau and Taiwan. Financial terms were not disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital